| scholarly article | Q13442814 |
| P50 | author | Céline Galès | Q73251493 |
| Marc Parmentier | Q96095332 | ||
| Jean-Yves Springael | Q123124182 | ||
| P2093 | author name string | Alexandre Huszagh | |
| Jenny Corbisier | |||
| P2860 | cites work | Biased and g protein-independent signaling of chemokine receptors | Q26823970 |
| A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. | Q31395542 | ||
| Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. | Q33291059 | ||
| Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans | Q34084671 | ||
| Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. | Q34134694 | ||
| A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine | Q34321618 | ||
| The importance of stereoselective determination of drugs in the clinical laboratory | Q35051388 | ||
| Biased signaling at chemokine receptors | Q35351711 | ||
| Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism. | Q35999789 | ||
| Therapeutic potential of β-arrestin- and G protein-biased agonists. | Q36773331 | ||
| Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. | Q36936400 | ||
| Biased agonism as a mechanism for differential signaling by chemokine receptors. | Q37368610 | ||
| Chemokines and chemokine receptors: an overview. | Q37409994 | ||
| Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy | Q37662609 | ||
| Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists | Q37706598 | ||
| CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. | Q37726647 | ||
| Signalling bias in new drug discovery: detection, quantification and therapeutic impact. | Q38081692 | ||
| Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication | Q39002273 | ||
| Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. | Q39030338 | ||
| Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. | Q39040325 | ||
| CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 | Q39144493 | ||
| Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity | Q39200573 | ||
| Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. | Q39464587 | ||
| Structural basis for the interaction of CCR5 with a small molecule, functionally selective CCR5 agonist | Q40241635 | ||
| Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7. | Q40323977 | ||
| Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. | Q40467514 | ||
| Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo | Q41603563 | ||
| Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers | Q42705103 | ||
| First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers | Q44339339 | ||
| Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4. | Q47989447 | ||
| Functional Selectivity and Biased Receptor Signaling | Q48656806 | ||
| The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors | Q51760841 | ||
| Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers | Q51822453 | ||
| Operational models of pharmacological agonism | Q52699226 | ||
| Metabolic and pharmacodynamic interactions of enantiomers of propoxyphene and methorphan | Q53729191 | ||
| Pharmacological characteristics of the stereoisomers of carvedilol | Q68093321 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enantiomer | Q494483 |
| bias | Q742736 | ||
| P304 | page(s) | 575-584 | |
| P577 | publication date | 2016-11-28 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5. | |
| P478 | volume | 292 |
| Q47231111 | Biased signalling: from simple switches to allosteric microprocessors |
| Q60046351 | CCR5 structural plasticity shapes HIV-1 phenotypic properties |
| Q59791974 | Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines |
| Q50130085 | Correspondence: Reply to 'Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury'. |
| Q57181974 | Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness |
| Q45930874 | Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model. |
| Q131901489 | Targeting the CCL2–CCR2 axis for atheroprotection |
Search more.